ALPN - IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role | Benzinga
RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate - povetacicept
The analysts Gregory Renza and Supawat Thongthip initiated with an Outperform rating and a price target of $19.
The analyst perceives povetacicept as having a robust foundation for advancement in autoimmune indications, primarily due to its emphasis on BAFF and APRIL, which are well-established therapeutic targets.
The IgAN, the primary focus of the RUBY-3 trial, holds substantial market potential (estimated at over $6 ...